An Immunohistochemical Study of Stathmin 1 Expression in Osteosarcoma Shows an Association with Metastases and Poor Patient Prognosis

Zhao, Changlei; Li, Yong; Wang, Lingling; Sun, Wei

doi:10.12659/msm.910953

Cited by 13 publications

(11 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It would be meaningful to investigate the real correlation between them in future research. Several previous studies showed stathmin could directly predict the prognosis of cancer patients, but we did not obtain accordant results in this study. The possible reason is that patients in this study, following the inclusion criteria for our clinical trial, were all at clinical stages III and IVA.…”

Section: Discussioncontrasting

confidence: 97%

Stathmin guides personalized therapy in oral squamous cell carcinoma

Long

Zhao

et al. 2020

Cancer Science

View full text Add to dashboard Cite

The survival benefit from docetaxel, cisplatin and 5-fluorouracil (TPF) induction chemotherapy in oral squamous cell carcinoma (OSCC) patients is not satisfactory.Previously, we identified that stathmin, a microtubule-destabilizing protein, is overexpressed in OSCC. Here, we further investigated its role as a biomarker that impacts on OSCC chemosensitivity. We analyzed the predictive value of stathmin on TPF induction chemotherapy and its impact on OSCC cell chemosensitivity. Then, we further investigated the therapeutic effects of the combination therapy of TPF chemotherapy and PI3K-AKT-mTOR inhibitors in vitro and in vivo. We found that OSCC patients with low stathmin expression benefited from TPF induction chemotherapy, while OSCC patients with high stathmin expression could not benefit from TPF induction chemotherapy. Stathmin overexpression promoted cellular proliferation and decreased OSCC cell sensitivity to TPF treatment. In addition, inhibition of the PI3K-AKT-mTOR signaling pathway decreased stathmin expression and phosphorylation.The combination therapy of TPF chemotherapy and PI3K-AKT-mTOR inhibitors exhibited a potent antitumor effect both in vitro and in vivo. Therefore, stathmin can be used as a predictive biomarker for TPF induction chemotherapy and a combination therapy regimen based on stathmin expression might improve the survival of OSCC patients. K E Y W O R D Sbiomarker, induction chemotherapy, oral squamous cell carcinoma, personalized therapy, translational medicine

show abstract

Section: Discussioncontrasting

confidence: 97%

Stathmin guides personalized therapy in oral squamous cell carcinoma

Long

Zhao

et al. 2020

Cancer Science

View full text Add to dashboard Cite

show abstract

“…Osteosarcoma is a primary malignant tumor common in adolescents or children under the age of 20. This disease has the following clinical features: strong invasiveness, poor prognosis, and high metastatic rate [13][14][15][16][17]. Although osteosarcoma is treated in a variety of ways, local tumor recurrence, metastasis, and multi-drug resistance after surgery and low rate of tumor necrosis at the time of the surgery seriously hamper the postoperative condition and prognosis of osteosarcoma patients [18,19].…”

Section: Discussionmentioning

confidence: 99%

Zinc promotes cell apoptosis via activating the Wnt-3a/β-catenin signaling pathway in osteosarcoma

Gao

Zhang²,

Niu

et al. 2020

J Orthop Surg Res

View full text Add to dashboard Cite

Background: The zinc content in the blood and tumor tissues of patients with osteosarcoma and the underlying regulation and molecular mechanism of zinc have not been reported.Methods and results: This study showed that the zinc content in the blood and tumor tissues of patients with osteosarcoma significantly reduced. CCK-8 and Transwell chamber assays revealed that zinc treatment significantly inhibited the proliferation and invasion abilities of osteosarcoma cells. Western blot analysis indicated that the expression levels of caspase-3 and caspase-9 were significantly increased, suggesting that zinc inhibited the growth and promoted the apoptosis of osteosarcoma cells. In addition, the expression levels of Wnt-3a and β-catenin, the marker proteins of the Wnt/β-catenin signaling pathways, were significantly increased in osteosarcoma cells after zinc intervention, which demonstrated that the pathway was clearly activated. However, the effect of zinc on the apoptosis, proliferation, and invasion abilities of osteosarcoma cells was reversed when the Wnt/β-catenin signaling pathways was inhibited by XAV939 (Wnt antagonist) treatment.Conclusions: This study is the first to report the changes in zinc levels in the blood and tumor tissues of patients with osteosarcoma and to preliminarily verify that zinc inhibits the proliferation and invasion and promote the apoptosis of osteosarcoma cells by inducing the Wnt/β-catenin signaling pathway, which ultimately inhibit cancer growth.

show abstract

“…Although these ve predictors were easy to obtain, it was undeniable that these predictors were all non-speci c OSC predictors and may lack certain speci city. Some biomarkers may be incorporated into these prognostic models to improve speci city, such as immunohistochemical markers [41], radiomics [42,43], and recently newly applied non-coding RNAs [44,45]. 5.…”

Section: Discussionmentioning

confidence: 99%

A Novel Prognostic Model to Predict Prognosis of Patients With Osteosarcoma Based on Clinical Characteristics and Blood Biomarkers

Tian

Chen

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: To develop a novel prognostic model based on clinical characteristics and blood biomarkers to estimate overall survival (OS) and progression-free survival (PFS) in osteosarcoma (OSC) patients.Methods: A total of 71 patients with OSC from Sun Yat-sen University Cancer Center were retrospectively included. The novel prognostic model for predicting OS and PFS was established by using Lasso regression analysis based on blood biomarkers. The predictive accuracy and discriminative ability of the novel prognostic model was compared with TNM staging and clinical treatment using concordance index (C-index), time-dependent ROC (tdROC) curve, decision curve analysis (DCA), net reclassification improvement index (NRI), and integrated discrimination improvement index (IDI).Results: Based on the Lasso regression analysis, we identified a 5 prognostic factors module (RBC, Ca2+, CRE, PNI, and LSR) as a novel predictive model for the OSC patients. The C-index of the novel prognostic model for predicting OS and PFS were 0.782 (95% CI = 0.658 - 0.905) and 0.741 (95% CI = 0.632 - 0.851), respectively, which were higher than that of TNM staging and clinical treatment. The tdROC curve and DCA also showed the novel model had good predictive accuracy and discriminatory power than TNM staging and treatment both in predicting OS and PFS. Moreover, the novel prognostic model performed well in all time frames (1, 3 and 5 years) in terms of the IDI and NRI when compared with the TNM staging, and clinical treatment.Conclusions: The novel prognostic model showed favorable performance than TNM staging and clinical treatment for predicting OS and PFS in OSC patients.

show abstract

An Immunohistochemical Study of Stathmin 1 Expression in Osteosarcoma Shows an Association with Metastases and Poor Patient Prognosis

Cited by 13 publications

References 27 publications

Stathmin guides personalized therapy in oral squamous cell carcinoma

Stathmin guides personalized therapy in oral squamous cell carcinoma

Zinc promotes cell apoptosis via activating the Wnt-3a/β-catenin signaling pathway in osteosarcoma

A Novel Prognostic Model to Predict Prognosis of Patients With Osteosarcoma Based on Clinical Characteristics and Blood Biomarkers

Contact Info

Product

Resources

About